Shares of the Australian real estate company, Dexus (ASX:DXS), plunged by up to 4.5% to A$7.65, marking its largest intra-day fall since late December of last year.

The decline comes as Dexus anticipates pressure on valuations of its real assets, with inflation and soaring interest rates impacting the company significantly.

Dexus also reported its first annual net loss since 2009, amounting to A$752.7 million.

Looking forward, the company conjectures a reduced distribution of 48 Australian cents per security, a dip compared with the current year’s total distribution of 51.6 cents.

The share value has reached its lowest point since late June, despite rising by 3.4% this year as of the most recent close.

Dexus (ASX:DXS) is an Australian based real estate company involved in owning, managing, and developing properties.

Shares of Australia’s FINEOS Corporation (ASX:FCL) fell 12.9% to A$0.22.

The company reported its FY23 EBITDA at 2 million euros ($2.18 million) after Tuesday’s market close, marking a 70.2% decrease from FY22 levels.

FINEOS also reported FY23 total revenue of 125 million euros, which is down 1.7% from FY22.

The stock has risen 67.2% this year, as of the last close.

The FINEOS Corporation (ASX:FCL) is a technology company that provides software solutions to insurance companies globally.

Shares of New Zealand’s Fletcher Building (ASX:FBU) witnessed a fall of as much as 4.4% sinking to NZ$5.250, their lowest point since June 29.

The company recently announced a net profit after tax of NZ$235 million for the year ending June 30, marking a decrease from the NZ$432 million reported the previous year.

Fletcher Building’s revenue for the fiscal year stood at NZ$8,469 million, a slight drop from the NZ$8,498 million recorded a year prior.

Further, the company declared a fully imputed final dividend of 16 cents per share.

The stock, tracing its biggest intraday fall since August 8, is up 16.3% this year, as of its last close.

Fletcher Building (ASX:FBU) is a multinational corporation involved in building and construction.

Recently, Mirvac Group (ASX:MGR) issued a statement foreseeing its FY24 distributions at 10.5 AU CPSS.

The company also aims to hit an operating earnings target between 14.0 and 14.3 AU CPSS for FY24.

Further bolstering its positive outlook is the continued sale of non-core assets to optimize capital allocation across its portfolio.

Not only is the group seeing good sales momentum due to an improved medium-term outlook, but it also plans to increase industry and living sector exposure over time.

With upcoming apartment project completions and planned launches in FY24 and FY25, Mirvac Group (ASX:MGR) is well-positioned to meet the anticipated demand in an undersupplied market.

Mirvac Group is a leading Australian property group, engaged in the investment and development of commercial and residential property.

Transurban Group (ASX:TCL) recently announced that they are in a solid position to increase distributions and provide long-term value to their shareholders.

They expect some benefits from the financial year 2023 inflation to persist into the revenue of the financial year 2024.

Transurban Group (ASX:TCL) also highlighted the strong traffic and EBITDA records in FY23, which they believe will provide a sturdy foundation for continuous growth in FY24.

The Group is currently engaging with the Australian Competition and Consumer Commission (ACCC) to address matters arising from Eastlink.

Transurban Group (ASX:TCL) is an Australian toll road company that operates and develops urban toll road networks in Australia and North America.

Transurban Group (ASX:TCL) has declared its final dividend of the year, totaling 31.5 Australian cents per share.

Additionally, the company reported fiscal year profit attributable at A$64 million, a rise of 211.3% from the previous year.

In the same period, revenue from ordinary activities increased by 22.1%, reaching A$4,157 million.

Looking forward to the fiscal year of 2024, the distribution is expected to be 62 Australian cents per share.

The company expects that new assets and long-term structural trends will continue to support traffic growth in the fiscal year 2024.

They also predict a growth in their pipeline of opportunities, which is expected to support distribution growth.

Moreover, the joint venture WestConnex is projected to benefit after the completion of the Rozelle Interchange in FY24.

Transurban Group is a global infrastructure company, operating multiple toll roads in Australia, North America and the United Kingdom.

Analysts from Jefferies and Morningstar have expressed lack of enthusiasm towards the outlook statement of Australia’s Seek, labeling the forecast as ‘disappointing’.

The employment services company issued a less than anticipated outlook for the fiscal year 2024, inducing a considerable drop in share prices.

According to Jefferies, the outlook seems to suggest stagnant or possibly a decline in earnings in comparison with fiscal year 2023.

On the same note, Morningstar predicts Seek may experience further deceleration in its Australia and New Zealand business by 2024.

Due to a projected decrease in Australia’s total vacancies from double the pre-COVID average to a trend level, Morningstar anticipates yields will eventually drop.

Among thirteen analysts, eight rate the stock ‘buy’, three recommend ‘hold’, and two suggest ‘sell’.

Their median target price for the stock is A$27.4, according to Refinitiv data.

Despite this, the stock has seen a surge of 17.7% this year as of its recent closing.

Seek (AX:SEK) is an employment services provider operating in Australia.

Transurban Group (ASX:TCL) has announced the appointment of Michelle Jablko as the Group’s new Chief Executive Officer.

Jablko is set to replace Scott Charlton, the current CEO.

The company has yet to make an announcement regarding the appointment of a replacement for the position of Chief Financial Officer.

Transurban Group (ASX:TCL) is a major Australian toll road operator.

Recent speculations indicate potential sales growth for GUD Holdings (ASX:GUD) from their AutoPacific Group, which was acquired earlier in 2022.

Financial analysts predict high sales growth for the fiscal year 2024 (FY24).

The automotive parts manufacturer recently reported an annual underlying net profit after tax of A$118.7 million, showing an increase of 33% from previous figures, along with increased revenue and EBITA growth for their APG business in FY24 expected.

According to estimates from Morningstar, AutoPacific’s sales are projected to grow by 7% in FY24, while Citi predicts a 24% growth in margins for the same fiscal year.

Citi analysts have noted GUD’s potential in the small cap auto parts sector, recognizing the continuous improvements made by APG, specifically in mitigating supply constraint issues.

Furthermore, Morningstar continues to hold its fair value estimate for GUD’s stock at A$12 per share, with a high uncertainty rating.

On the other hand, Citi has increased their price target to A$13.30 per share and advise to buy.

Out of nine, eight analysts encourage buying or rating the stock higher, one suggests holding, while none recommend selling or downgrading; their median price target is A$11.78.

As of the latest closing, GUD’s stock has witnessed an approximate increase of 54.9% this year.

GUD Holdings (ASX:GUD) is a leading automotive parts manufacturer based in Australia.

Citi has revised its price target for Australian biotech firm CSL (ASX:CSL), following a robust increase in its annual earnings.

The finance conglomerate enhanced its Price Target (PT) from A$340 to A$325, reaffirming its ‘buy’ rating for the company.

The revision comes after an 8% augmentation in CSL’s FY23 NPAT attributable on a Constant Currency (CC) basis, accruing to $2.44 billion, with a reported revenue surge of 31% at $13.31 billion on CC.

The organisation anticipates that current foreign exchange volatility impacts will be negligible on CSL’s NPAT attributable.

It also projects sales of immunoglobulin (Ig) to experience an approximate 8% annual growth.

Behring, CSL’s plasma collection unit, is also expected to witness an Ig sales growth of around 20%, resulting in approximately 125 basis points improvement in the FY24 gross margin.

According to Refinitiv data, out of 19 analysts that have assessed the stock, 16 have recommended ‘buy’ or higher, 2 have suggested ‘hold’ and 1 has advised ‘sell’ with the median PT standing at A$325.

As per the last close, the stock is down 8.6% this year.

CSL is an Australian biotech firm specializing in biotherapies, influenza vaccines and blood plasma fractions.